July 28, 2021 -- Kiromic Biopharma has purchased bioinformatics and artificial intelligence (AI) firm InSilico Solutions.
The deal will enhance Kiromic's efforts to develop AI technology for selecting the optimal biomarkers needed for immunotherapeutics such as CAR T-cell therapy, according to the company.
Image courtesy of Kiromic.
InSilico's analytical tools enable the extraction of biological information from various genomic data sources. Kiromic said it is focusing now on developing models using whole-genome sequencing, RNA sequencing, single-cell RNA sequencing, cytometry, and cytokine panels to assist in selecting donor T cells with the strongest therapeutic potential.
Data from clinical trials will be utilized to improve treatment protocols and patient selection, according to InSilico. The goal is to accelerate therapeutic development, manufacturing, and clinical testing of Kiromic's off-the-shelf allogeneic CAR T for solid tumors, the firm said.
Copyright © 2021 scienceboard.net